Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Purified exosome product - RION

Drug Profile

Purified exosome product - RION

Alternative Names: 10% PEP; 20% PEP; PEP; PEPTM; Purified Exosome ProductTM

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mayo Foundation for Medical Education and Research
  • Developer Mayo Foundation for Medical Education and Research; RION
  • Class Blood products and substitutes; Exosome therapies
  • Mechanism of Action Angiogenesis inducing agents; Exosome replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic foot ulcer
  • Phase I Myocardial infarction
  • Preclinical Alopecia; Joint disorders; Urinary incontinence
  • No development reported Wounds
  • Discontinued Crohn's disease

Most Recent Events

  • 07 May 2024 RION anticipates to submit a Biologics License Application (BLA) for purified exosome product for Diabetic foot ulcers
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Wounds in USA (Parenteral)
  • 30 Jan 2024 Phase-II clinical trials in Diabetic foot ulcer in USA (Parenteral) before January 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top